Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Iron Deficiencies 1Carcinoma, Ovarian Epithelial 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

AP 1903 reagent 2thymoglobulin 1obinutuzumab 1fosphenytoin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Thiotepa 1Phenytoin 1Moxibustion 1Melphalan 1Ferric Oxide, Saccharated 1Darbepoetin alfa 1Cyclophosphamide 1CP protocol 1Busulfan 1Antilymphocyte Serum 1Alemtuzumab 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anemia × Ferric Oxide, Saccharated × Clear all
NCT03933813 2023-01-05

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

University of Wisconsin, Madison

Phase 1/2 Terminated
9 enrolled
Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Iron Deficiencies, Anemia, Ovarian Neoplasms, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡